Work

And… We’re Back: The Reemergence of CD137 in Cancer Immunotherapy via Antigen Anchoring

Year: 2025

Type: article

Abstract: Drug development targeting CD137 has been historically fraught because of concerns over safety and efficacy. A deeper understanding of CD137 function and insights into why earlier CD137 agonists failed have set the stage for a new generation of promising CD137 therapeutics. See related article by de Bono et al., p. 3388.

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-25-1089

Authors: Matthew K. Nguyen, Jason J. Luke

Institutions: University of Pittsburgh, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute